BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
VERX upcoming catalysts
Vertex Pharmaceuticals Incorporated: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 5 readout(s) and 3 FDA event(s). Subscribe to VERX (.ics).
Drugs: Suzetrigine
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01-25 est. | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT06696443 Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | Diabetic Peripheral Neuropathic Pain | active not recruiting | 455 |
| 2027-02-02 est. | P1/P2 | Vertex Pharmaceuticals Incorporated VERX | NCT06185764 A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | Myotonic Dystrophy Type 1 (DM1) | active not recruiting | 47 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-03-27 | FDA approval | approved | VERTEX PHARMS INC VERX | TRIKAFTA | Approved 2026-03-27: TRIKAFTA (COPACKAGED) (NDA212273 SUPPL14) |
| 2026-03-27 | FDA approval | approved | VERTEX PHARMS INC VERX | ALYFTREK | Approved 2026-03-27: ALYFTREK (NDA218730 SUPPL1) |
| 2026-03-27 | FDA approval | approved | VERTEX PHARMS INC VERX | TRIKAFTA | Approved 2026-03-27: TRIKAFTA (COPACKAGED) (NDA217660 SUPPL8) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-30 est. | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT05444257 A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | Cystic Fibrosis | active not recruiting | 822 |
| 2026-09-17 est. | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT06832410 An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | Type 1 Diabetes; Kidney Transplant | recruiting | 10 |
| 2026-07-20 | P2 | Vertex Pharmaceuticals Incorporated VERX | NCT06794996 Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities | Proteinuric Kidney Disease | completed | 42 |
| 2026-04-21 | P1/P2 | Vertex Pharmaceuticals Incorporated VERX | NCT05668741 A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | Cystic Fibrosis | completed | 26 |
| 2026-01-29 | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT05153317 Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older | Cystic Fibrosis | completed | 71 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.